GlucoTrack (NASDAQ:GCTK) Shares Down 8.7% – Should You Sell?

Shares of GlucoTrack, Inc. (NASDAQ:GCTK) traded down 8.7% on Thursday . The company traded as low as $6.84 and last traded at $6.89. 246,630 shares traded hands during trading, a decline of 94% from the average session volume of 4,128,916 shares. The stock had previously closed at $7.55.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised GlucoTrack to a “sell” rating in a report on Saturday, June 21st.

GlucoTrack Stock Down 8.7%

The company has a debt-to-equity ratio of 0.03, a current ratio of 3.27 and a quick ratio of 3.27. The stock has a market capitalization of $6.20 million, a P/E ratio of -0.12 and a beta of -0.17. The firm has a 50-day simple moving average of $5.93 and a 200 day simple moving average of $9.09.

GlucoTrack (NASDAQ:GCTK) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($9.62) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On GlucoTrack

A hedge fund recently raised its stake in GlucoTrack stock. Bank of America Corp DE raised its holdings in GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,089 shares of the company’s stock after buying an additional 4,085 shares during the period. Bank of America Corp DE owned about 0.85% of GlucoTrack worth $25,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.92% of the company’s stock.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.